I
Intrance Medical Systems
A private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease (a subsidiary of Intrance Holdings…
About Intrance Medical Systems
Intrance Medical Systems, Inc. operates as a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for advanced Parkinson’s disease (APD). Established in 2018, the firm was an independent spin-out from the Sweden-based Lobsor Pharmaceuticals AB. The company's efforts are concentrated on bringing its lead product to markets including the U.S., Canada, South America, Japan, and Taiwan, where it holds all intellectual property and commercial rights.
The company's history is rooted in the extensive experience of its founders, Ulf Rosén and Roger Bolsöy. Both held key executive roles at companies like NeoPharma, Solvay, and AbbVie, where they were involved in the development and commercialization of a levodopa-carbidopa intestinal gel, a recognized therapy for APD. Leveraging this background, they founded Lobsor Pharmaceuticals and developed a patented gel formulation in 2013 to address unmet needs in APD treatment. This led to the creation of Intrance Medical Systems to handle commercialization in specific international markets. In September 2020, STADA's Britannia Pharmaceuticals acquired Lobsor, while Intrance retained its specified territorial rights.
Intrance Medical Systems is advancing a drug-device combination therapy, known in Europe as Lecigon®. This product is a fixed-dose gel formulation combining three active substances: levodopa, carbidopa, and entacapone. It is designed for continuous enteral infusion directly into the small intestine via a lightweight, wearable pump. This method of delivery bypasses the stomach, which can be beneficial as oral medication can become less effective in the later stages of Parkinson's due to issues like erratic gastric emptying. The addition of entacapone to the formula increases the bioavailability of levodopa, which allows for lower doses and the use of a smaller pump, weighing just 134 grams, enhancing patient convenience.
The company's business model centers on gaining regulatory approval and commercializing this specialized therapy for patients with advanced Parkinson's disease. Lecigon® has already been approved and is commercially available in several European countries, where it has seen positive market uptake. To fund its U.S. clinical development program, Intrance completed a Series A financing round in 2022, raising a total of $17 million, with notable investors including Erik Selin and Rutger Arnhult. The company has received FDA clearance for its Investigational New Drug (IND) application and is proceeding with its clinical trials in the United States.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2022 | $17M | $68M | Rutger Arnhult · Erik Selin | ↗ |
| SERIES A✓Equity / VC | Nov 2021 | $3M | $40M | Rutger Arnhult | ↗ |
Growth signals
Latest recorded traffic for Intrance Medical Systems is 1.7K monthly website visits, up 304.8% over the last three months. Intrance Medical Systems's team grew 40% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Intrance Medical Systems in the New York City ecosystem
The Intrance Medical Systems office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- ESErik Selin
- RARutger Arnhult
Other known investors1 additional known investor
- MAM2 Asset Management AB
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Intrance Medical Systems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Intrance Medical Systems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









